Judit Váradi

Dr. Judit Váradi

University of Debrecen, Faculty of Pharmacy, Debrecen, Hajdú-Bihar, Hungary
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2010 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
TKT. Kiss
T. Kiss
Ferenc FenyvesiFerenc Fenyvesi
Ferenc Fenyvesi
IBI. Bácskay
I. Bácskay
Judit VáradiJudit Váradi
Judit Váradi
ÉFÉ. Fenyvesi
É. Fenyvesi
MVM. Vecsernyés
M. Vecsernyés

1 October 2012 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
ZUZoltán Ujhelyi
Zoltán Ujhelyi
Ferenc FenyvesiFerenc Fenyvesi
Ferenc Fenyvesi
Judit VáradiJudit Váradi
Judit Váradi
PFPálma Fehér
Pálma Fehér
TKTímea Kiss
Tímea Kiss
IBIldikó Bácskay
Ildikó Bácskay

20 November 2019 in Scientia Pharmaceutica
Verified
Journal Article
Open access
PDF file
Adam HaimhofferAdam Haimhoffer
Adam Haimhoffer
Ágnes RusznyákÁgnes Rusznyák
Ágnes Rusznyák
KRKatalin Réti-Nagy
Katalin Réti-Nagy
Gabor VasvariGabor Vasvari
Gabor Vasvari
Judit VáradiJudit Váradi
Judit Váradi
Ferenc FenyvesiFerenc Fenyvesi
Ferenc Fenyvesi
Cyclodextrins are widely used excipients, composed of glucopyranose units with a cyclic structure. One of their most important properties, is that their inner cavity is hydrophobic, while their surface is hydrophilic. This enables them for the complex formation with lipophilic molecules. They have several applications in the pharmaceutical field like solubility enhancers or the building blocks of larger drug delivery systems. On the other hand, they have numerous effects on cells or biological barriers. In this review the most important properties of cyclodextrins and cyclodextrin-based drug delivery systems are summarized with special focus on their biological activity.

1 February 2008 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
ILIstvan Lekli
Istvan Lekli
GSGergo Szabo
Gergo Szabo
BJBela Juhasz
Bela Juhasz
SDSamarjit Das
Samarjit Das
MDManika Das
Manika Das
ATArpad Tosaki
Arpad Tosaki
The resveratrol-induced cardiac protection was studied in Zucker obese rats. Rats were divided into five groups: group 1, lean control; group 2, obese control (OC); group 3, obese rats treated orally with 5 mg·kg−1·day−1 of resveratrol (OR) for 2 wk; group 4, obese rats received 10% glucose solution ad libitum for 3 wk (OG); and group 5, obese rats received 10% glucose for 3 wk and resveratrol (OGR) during the 2nd and 3rd wk. Body weight, serum glucose, and insulin were measured, and then hearts were isolated and subjected to 30 min of ischemia followed by 120 min of reperfusion. Heart rate, coronary flow, aortic flow, developed pressure, the incidence of reperfusion-induced ventricular fibrillation, and infarct size were measured. Resveratrol reduced body weight and serum glucose in the OR compared with the OC values (414 ± 10 g and 7.08 ± 0.41 mmol/l, respectively, to 378 ± 12 g and 6.11 ± 0.44 mmol/l), but insulin levels were unchanged. The same results were obtained for the OG vs. OGR group. Resveratrol improved postischemic cardiac function in the presence or absence of glucose intake compared with the resveratrol-free group. The incidence of ventricular fibrillation and infarct size was reduced by 83 and 20% in the OR group, and 67 and 16% in the OGR group, compared with the OC and OG groups, respectively. Resveratrol increased GLUT-4 expression and reduced endothelin expression and cardiac apoptosis in ischemic-reperfused hearts in the presence or absence of glucose intake. Thus the protective effect of resveratrol could be related to its direct effects on the heart.

11 November 2015 in Molecules
Verified
Journal Article
Open access
PDF file
EREszter Róka
Eszter Róka
Zoltán UjhelyiZoltán Ujhelyi
Zoltán Ujhelyi
Maria DeliMaria Deli
Maria Deli
ABAlexandra Bocsik
Alexandra Bocsik
Eva FenyvesiEva Fenyvesi
Eva Fenyvesi
Dr Bácskay Katalin IldikóDr Bácskay Katalin Ildikó
Dr Bácskay Katalin Ildikó
Cyclodextrins, even the 6-membered α-cyclodextrin, are approved in the various pharmacopoeias as pharmaceutical excipients for solubilizing and stabilizing drugs as well as for controlling drug release. Recently α-cyclodextrin has also been marketed as health food with beneficial effects on blood lipid profiles. However, the concentration of α-cyclodextrin used may be very high in these cases, and its toxic attributes have to be seriously considered. The objective of this study was to investigate the cytotoxicity of various, differently substituted α-cyclodextrin derivatives and determine relationship between the structures and cytotoxicity. Three different methods were used, viability tests (MTT assay and Real Time Cell Electronic Sensing on Caco-2 cells) as well as hemolysis test on human red blood cells. The effect of α-cyclodextrin derivatives resulted in concentration-dependent cytotoxicity, so the IC50 values have been determined. Based on our evaluation, the Real Time Cell Electronic Sensing method is the most accurate for describing the time and concentration dependency of the observed toxic effects. Regarding the cytotoxicity on Caco-2 cells, phosphatidylcholine extraction may play a main role in the mechanism. Our results should provide help in selecting those α-cyclodextrin derivatives which have the potential of being used safely in medical formulations.

1 August 2008 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
Ferenc FenyvesiFerenc Fenyvesi
Ferenc Fenyvesi
Eva FenyvesiEva Fenyvesi
Eva Fenyvesi
LSLajos Szente
Lajos Szente
KGKatalin Goda
Katalin Goda
ZBZsolt Bacso
Zsolt Bacso
MVMiklós Vecsernyés
Miklós Vecsernyés